首页 > 最新文献

Radiation oncology journal最新文献

英文 中文
Lattice radiotherapy in inflammatory breast cancer: report of a first case treated with curative aim. 炎症性乳腺癌的格子放射治疗:首例治愈病例报告。
Pub Date : 2024-06-01 Epub Date: 2024-06-25 DOI: 10.3857/roj.2024.00038
Silvana Parisi, Miriam Sciacca, Paola Critelli, Giacomo Ferrantelli, Federico Chillari, Valeria Venuti, Claudio Napoli, Issa Shteiwi, Carmelo Siragusa, Anna Brogna, Antonio Pontoriero, Gianluca Ferini, Anna Santacaterina, Stefano Pergolizzi

Inflammatory breast cancer (IBC) is a rare, aggressive form of breast cancer characterized by poor prognosis. The treatment requires a multidisciplinary approach, with neoadjuvant chemotherapy, surgery, and radiation therapy (RT). Particularly, high doses of conventional RT have been historically delivered in the adjuvant setting after chemotherapy and mastectomy or as radical treatment in patients ineligible for surgery. Here, we report the case of a 49-year-old woman patient with IBC unsuitable for surgery and treated with a combination of lattice RT and fractionated external beam RT concurrent with trastuzumab, with a curative aim. One year after RT, the patient showed a complete response and tolerable toxicities. This is the first reported case of a not-operable IBC patient treated with this particular kind of RT.

炎性乳腺癌(IBC)是一种罕见的侵袭性乳腺癌,预后较差。治疗需要采用多学科方法,包括新辅助化疗、手术和放疗(RT)。特别是,大剂量常规 RT 一直以来都是在化疗和乳房切除术后的辅助治疗中使用,或作为不符合手术条件的患者的根治性治疗。在此,我们报告了一例不适合手术的 49 岁 IBC 女性患者的病例,她在接受曲妥珠单抗治疗的同时,接受了格位 RT 和分次体外射束 RT 的联合治疗,以达到治愈目的。RT 治疗一年后,患者出现完全反应,毒性反应可耐受。这是首例报告的无法手术的 IBC 患者接受这种特殊 RT 治疗的病例。
{"title":"Lattice radiotherapy in inflammatory breast cancer: report of a first case treated with curative aim.","authors":"Silvana Parisi, Miriam Sciacca, Paola Critelli, Giacomo Ferrantelli, Federico Chillari, Valeria Venuti, Claudio Napoli, Issa Shteiwi, Carmelo Siragusa, Anna Brogna, Antonio Pontoriero, Gianluca Ferini, Anna Santacaterina, Stefano Pergolizzi","doi":"10.3857/roj.2024.00038","DOIUrl":"10.3857/roj.2024.00038","url":null,"abstract":"<p><p>Inflammatory breast cancer (IBC) is a rare, aggressive form of breast cancer characterized by poor prognosis. The treatment requires a multidisciplinary approach, with neoadjuvant chemotherapy, surgery, and radiation therapy (RT). Particularly, high doses of conventional RT have been historically delivered in the adjuvant setting after chemotherapy and mastectomy or as radical treatment in patients ineligible for surgery. Here, we report the case of a 49-year-old woman patient with IBC unsuitable for surgery and treated with a combination of lattice RT and fractionated external beam RT concurrent with trastuzumab, with a curative aim. One year after RT, the patient showed a complete response and tolerable toxicities. This is the first reported case of a not-operable IBC patient treated with this particular kind of RT.</p>","PeriodicalId":94184,"journal":{"name":"Radiation oncology journal","volume":"42 2","pages":"160-165"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11215509/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141474130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluating psychological anxiety in patients receiving radiation therapy using smartwatch. 使用智能手表评估接受放射治疗的患者的心理焦虑。
Pub Date : 2024-06-01 Epub Date: 2024-06-26 DOI: 10.3857/roj.2023.01067
Sangwoon Jeong, Chanil Jeon, Dongyeon Lee, Won Park, Hongryull Pyo, Youngyih Han

Purpose: Patients undergoing radiation therapy (RT) often experience psychological anxiety that manifests as muscle contraction. Our study explored psychological anxiety in these patients by using biological signals recorded using a smartwatch.

Materials and methods: Informed consent was obtained from participating patients prior to the initiation of RT. The patients wore a smartwatch from the waiting room until the conclusion of the treatment. The smartwatch acquired data related to heart rate features (average, minimum, and maximum) and stress score features (average, minimum, and maximum). On the first day of treatment, we analyzed the participants' heart rates and stress scores before and during the treatment. The acquired data were categorized according to sex and age. For patients with more than three days of data, we observed trends in heart rate during treatment relative to heart rate before treatment (HRtb) over the course of treatment. Statistical analyses were performed using the Wilcoxon signed-rank test and paired t-test.

Results: Twenty-nine individuals participated in the study, of which 17 had more than 3 days of data. During treatment, all patients exhibited elevated heart rates and stress scores, particularly those in the younger groups. The HRtb levels decreased as treatment progresses.

Conclusion: Patients undergoing RT experience notable psychological anxiety, which tends to diminish as the treatment progresses. Early stage interventions are crucial to alleviate patient anxiety during RT.

目的:接受放射治疗(RT)的患者经常会出现心理焦虑,表现为肌肉收缩。我们的研究通过使用智能手表记录的生物信号来探讨这些患者的心理焦虑:在开始 RT 治疗前,我们征得了参与患者的知情同意。患者从候诊室开始佩戴智能手表,直到治疗结束。智能手表获取与心率特征(平均值、最小值和最大值)和压力评分特征(平均值、最小值和最大值)相关的数据。在治疗的第一天,我们分析了参与者在治疗前和治疗过程中的心率和压力评分。获得的数据根据性别和年龄进行分类。对于数据超过三天的患者,我们观察了治疗期间心率相对于治疗前心率(HRtb)在治疗过程中的变化趋势。统计分析采用 Wilcoxon 符号秩检验和配对 t 检验:29 人参与了研究,其中 17 人有超过 3 天的数据。在治疗过程中,所有患者都表现出心率和压力评分升高,尤其是年轻组患者。随着治疗的进行,HRtb 水平有所下降:结论:接受 RT 治疗的患者会有明显的心理焦虑,这种焦虑会随着治疗的进展而减轻。早期干预对减轻 RT 患者的焦虑至关重要。
{"title":"Evaluating psychological anxiety in patients receiving radiation therapy using smartwatch.","authors":"Sangwoon Jeong, Chanil Jeon, Dongyeon Lee, Won Park, Hongryull Pyo, Youngyih Han","doi":"10.3857/roj.2023.01067","DOIUrl":"10.3857/roj.2023.01067","url":null,"abstract":"<p><strong>Purpose: </strong>Patients undergoing radiation therapy (RT) often experience psychological anxiety that manifests as muscle contraction. Our study explored psychological anxiety in these patients by using biological signals recorded using a smartwatch.</p><p><strong>Materials and methods: </strong>Informed consent was obtained from participating patients prior to the initiation of RT. The patients wore a smartwatch from the waiting room until the conclusion of the treatment. The smartwatch acquired data related to heart rate features (average, minimum, and maximum) and stress score features (average, minimum, and maximum). On the first day of treatment, we analyzed the participants' heart rates and stress scores before and during the treatment. The acquired data were categorized according to sex and age. For patients with more than three days of data, we observed trends in heart rate during treatment relative to heart rate before treatment (HRtb) over the course of treatment. Statistical analyses were performed using the Wilcoxon signed-rank test and paired t-test.</p><p><strong>Results: </strong>Twenty-nine individuals participated in the study, of which 17 had more than 3 days of data. During treatment, all patients exhibited elevated heart rates and stress scores, particularly those in the younger groups. The HRtb levels decreased as treatment progresses.</p><p><strong>Conclusion: </strong>Patients undergoing RT experience notable psychological anxiety, which tends to diminish as the treatment progresses. Early stage interventions are crucial to alleviate patient anxiety during RT.</p>","PeriodicalId":94184,"journal":{"name":"Radiation oncology journal","volume":"42 2","pages":"148-153"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11215504/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141474128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of histology on the outcome of sinonasal carcinomas treated with radiotherapy: a single institution experience. 组织学对鼻窦癌放疗疗效的影响:一家医疗机构的经验。
Pub Date : 2024-06-01 Epub Date: 2024-05-30 DOI: 10.3857/roj.2022.00514
Ali Kazemian, Borna Farazmand, Maryam Taherioun, Mahdie Razmkhah, Mohammad Shirkhoda, Amirmohsen Jalaeefar, Ata Garajei, Mehrdad Jafari, Farrokh Heidari, Mahdi Aghili, Reza Ghalehtaki

Purpose: Sinonasal malignancies are a rare group of head and neck cancers. We aimed to report the oncological outcomes based on histological types in patients who underwent radiotherapy.

Materials and methods: In this single-institution study, we retrospectively retrieved and analyzed data of patients with sinonasal carcinomas who underwent radiotherapy during 2011-2016 as part of their treatment. The 3-year rate of local, regional, and distant recurrences, and overall survival were evaluated according to the histological type.

Results: A total of 28 patients were evaluated in this study, the majority of whom were male (60%). Squamous cell carcinoma (SCC), adenoid cystic carcinoma (ACC), and adenocarcinoma (ADC) were found in 15 patients (53.5%), 8 (28.5%), and 5 (18%), respectively. The highest rates of local and regional recurrences were observed in ACC and SCC, respectively. Distant recurrences were numerically more common in ADC. The 3-year OS was 48%, 50%, and 73% in SCC, ADC, and ACC, respectively.

Conclusion: Different histopathologies of sinonasal cancer seem to have different patterns of failure, and this may be considered in the treatment approach.

目的:鼻窦恶性肿瘤是一类罕见的头颈部癌症。我们旨在报告接受放射治疗的患者根据组织学类型得出的肿瘤学结果:在这项单一机构研究中,我们回顾性检索并分析了 2011-2016 年期间接受放疗的鼻窦癌患者的数据,作为治疗的一部分。根据组织学类型评估了3年的局部、区域和远处复发率以及总生存率:本研究共评估了 28 名患者,其中大部分为男性(60%)。发现鳞状细胞癌(SCC)、腺样囊性癌(ACC)和腺癌(ADC)的患者分别为 15 人(53.5%)、8 人(28.5%)和 5 人(18%)。ACC 和 SCC 的局部和区域复发率分别最高。远处复发在 ADC 中更为常见。SCC、ADC和ACC的3年OS分别为48%、50%和73%:结论:不同组织病理学的鼻窦癌似乎有不同的失败模式,这一点可在治疗方法中加以考虑。
{"title":"The role of histology on the outcome of sinonasal carcinomas treated with radiotherapy: a single institution experience.","authors":"Ali Kazemian, Borna Farazmand, Maryam Taherioun, Mahdie Razmkhah, Mohammad Shirkhoda, Amirmohsen Jalaeefar, Ata Garajei, Mehrdad Jafari, Farrokh Heidari, Mahdi Aghili, Reza Ghalehtaki","doi":"10.3857/roj.2022.00514","DOIUrl":"10.3857/roj.2022.00514","url":null,"abstract":"<p><strong>Purpose: </strong>Sinonasal malignancies are a rare group of head and neck cancers. We aimed to report the oncological outcomes based on histological types in patients who underwent radiotherapy.</p><p><strong>Materials and methods: </strong>In this single-institution study, we retrospectively retrieved and analyzed data of patients with sinonasal carcinomas who underwent radiotherapy during 2011-2016 as part of their treatment. The 3-year rate of local, regional, and distant recurrences, and overall survival were evaluated according to the histological type.</p><p><strong>Results: </strong>A total of 28 patients were evaluated in this study, the majority of whom were male (60%). Squamous cell carcinoma (SCC), adenoid cystic carcinoma (ACC), and adenocarcinoma (ADC) were found in 15 patients (53.5%), 8 (28.5%), and 5 (18%), respectively. The highest rates of local and regional recurrences were observed in ACC and SCC, respectively. Distant recurrences were numerically more common in ADC. The 3-year OS was 48%, 50%, and 73% in SCC, ADC, and ACC, respectively.</p><p><strong>Conclusion: </strong>Different histopathologies of sinonasal cancer seem to have different patterns of failure, and this may be considered in the treatment approach.</p>","PeriodicalId":94184,"journal":{"name":"Radiation oncology journal","volume":"42 2","pages":"116-123"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11215502/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141474169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hypofractionated radiation therapy combined with androgen deprivation therapy for clinically node-positive prostate cancer. 低分次放射治疗结合雄激素剥夺疗法治疗临床结节阳性前列腺癌。
Pub Date : 2024-06-01 Epub Date: 2024-06-25 DOI: 10.3857/roj.2024.00080
Tae Hoon Lee, Hongryull Pyo, Gyu Sang Yoo, Seong Soo Jeon, Seong Il Seo, Byong Chang Jeong, Hwang Gyun Jeon, Hyun Hwan Sung, Minyong Kang, Wan Song, Jae Hoon Chung, Bong Kyung Bae, Won Park

Purpose: This study aimed to analyze the treatment outcomes of combined definitive radiation therapy (RT) and androgen deprivation therapy (ADT) for clinically node-positive prostate cancer.

Materials and methods: Medical records of 60 patients with clinically suspected metastatic lymph nodes on radiological examination were retrospectively analyzed. Eight patients (13.3%) were suspected to have metastatic common iliac or para-aortic lymph nodes. All patients underwent definitive RT with a dose fractionation of 70 Gy in 28 fractions. ADT was initiated 2-3 months before RT and continued for at least 2 years. Biochemical failure rate (BFR), clinical failure rate (CFR), overall survival (OS), and prostate cancer-specific survival (PCSS) were calculated, and genitourinary and gastrointestinal adverse events were recorded.

Results: The median follow-up period was 5.47 years. The 5-year BFR, CFR, OS, and PCSS rates were 19.1%, 11.3%, 89.0%, and 98.2%, respectively. The median duration of ADT was 2.30 years. BFR and CFR increased after 3 years, and 11 out of 14 biochemical failures occurred after the cessation of ADT. Grade 2 and beyond late genitourinary and gastrointestinal toxicity rates were 5.0% and 13.3%, respectively. However, only two grade 3 adverse events were reported, and no grade 4-5 adverse events were reported. Patients with non-regional lymph node metastases did not have worse BFR, CFR, or adverse event rates.

Conclusion: This study reported the efficacy and tolerable toxicity of hypofractionated definitive RT combined with ADT for clinically node-positive prostate cancer. Additionally, selected patients with adjacent non-regional lymph node metastases might be able to undergo definitive RT combined with ADT.

目的:本研究旨在分析确定性放疗(RT)和雄激素剥夺疗法(ADT)联合治疗临床结节阳性前列腺癌的疗效:回顾性分析了60例经放射学检查临床疑似淋巴结转移患者的病历。8名患者(13.3%)被怀疑有髂总淋巴结或主动脉旁淋巴结转移。所有患者都接受了明确的 RT 治疗,剂量为 70 Gy,分 28 次进行。ADT 在 RT 前 2-3 个月开始,持续至少 2 年。计算生化失败率(BFR)、临床失败率(CFR)、总生存率(OS)和前列腺癌特异性生存率(PCSS),并记录泌尿生殖系统和胃肠道不良事件:中位随访时间为5.47年。5年BFR、CFR、OS和PCSS率分别为19.1%、11.3%、89.0%和98.2%。ADT 的中位持续时间为 2.30 年。BFR和CFR在3年后有所增加,14例生化失败中有11例发生在ADT停止后。2级及以上的晚期泌尿生殖系统和胃肠道毒性发生率分别为5.0%和13.3%。不过,仅报告了两例3级不良事件,未报告4-5级不良事件。非区域性淋巴结转移患者的BFR、CFR或不良事件发生率并没有降低:本研究报告了低分次明确RT联合ADT治疗临床结节阳性前列腺癌的疗效和可耐受毒性。此外,一些邻近非区域淋巴结转移的患者也可以接受明确RT联合ADT治疗。
{"title":"Hypofractionated radiation therapy combined with androgen deprivation therapy for clinically node-positive prostate cancer.","authors":"Tae Hoon Lee, Hongryull Pyo, Gyu Sang Yoo, Seong Soo Jeon, Seong Il Seo, Byong Chang Jeong, Hwang Gyun Jeon, Hyun Hwan Sung, Minyong Kang, Wan Song, Jae Hoon Chung, Bong Kyung Bae, Won Park","doi":"10.3857/roj.2024.00080","DOIUrl":"10.3857/roj.2024.00080","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to analyze the treatment outcomes of combined definitive radiation therapy (RT) and androgen deprivation therapy (ADT) for clinically node-positive prostate cancer.</p><p><strong>Materials and methods: </strong>Medical records of 60 patients with clinically suspected metastatic lymph nodes on radiological examination were retrospectively analyzed. Eight patients (13.3%) were suspected to have metastatic common iliac or para-aortic lymph nodes. All patients underwent definitive RT with a dose fractionation of 70 Gy in 28 fractions. ADT was initiated 2-3 months before RT and continued for at least 2 years. Biochemical failure rate (BFR), clinical failure rate (CFR), overall survival (OS), and prostate cancer-specific survival (PCSS) were calculated, and genitourinary and gastrointestinal adverse events were recorded.</p><p><strong>Results: </strong>The median follow-up period was 5.47 years. The 5-year BFR, CFR, OS, and PCSS rates were 19.1%, 11.3%, 89.0%, and 98.2%, respectively. The median duration of ADT was 2.30 years. BFR and CFR increased after 3 years, and 11 out of 14 biochemical failures occurred after the cessation of ADT. Grade 2 and beyond late genitourinary and gastrointestinal toxicity rates were 5.0% and 13.3%, respectively. However, only two grade 3 adverse events were reported, and no grade 4-5 adverse events were reported. Patients with non-regional lymph node metastases did not have worse BFR, CFR, or adverse event rates.</p><p><strong>Conclusion: </strong>This study reported the efficacy and tolerable toxicity of hypofractionated definitive RT combined with ADT for clinically node-positive prostate cancer. Additionally, selected patients with adjacent non-regional lymph node metastases might be able to undergo definitive RT combined with ADT.</p>","PeriodicalId":94184,"journal":{"name":"Radiation oncology journal","volume":"42 2","pages":"139-147"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11215505/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141474129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hypofractionated radiation therapy for head and neck cancers in the era of intensity-modulated radiation therapy. 在调强放射治疗时代,头颈部癌症的低分次放射治疗。
Pub Date : 2024-03-01 Epub Date: 2024-03-26 DOI: 10.3857/roj.2024.00178
Keun-Yong Eom
{"title":"Hypofractionated radiation therapy for head and neck cancers in the era of intensity-modulated radiation therapy.","authors":"Keun-Yong Eom","doi":"10.3857/roj.2024.00178","DOIUrl":"10.3857/roj.2024.00178","url":null,"abstract":"","PeriodicalId":94184,"journal":{"name":"Radiation oncology journal","volume":"42 1","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10982057/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140320258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Interobserver delineation variability of computed tomography-based radiomic features of the parotid gland. 基于计算机断层扫描的腮腺放射学特征在观察者之间的差异。
Pub Date : 2024-03-01 Epub Date: 2024-02-21 DOI: 10.3857/roj.2023.00605
Kanyapat Buasawat, Sasikarn Chamchod, Todsaporn Fuangrod, Sawanee Suntiwong, Thiansin Liamsuwan

Purpose: To assess the interobserver delineation variability of radiomic features of the parotid gland from computed tomography (CT) images and evaluate the correlation of these features for head and neck cancer (HNC) radiotherapy patients.

Materials and methods: Contrast-enhanced CT images of 20 HNC patients were utilized. The parotid glands were delineated by treating radiation oncologists (ROs), a selected RO and AccuContour auto-segmentation software. Dice similarity coefficients (DSCs) between each pair of observers were calculated. A total of 107 radiomic features were extracted, whose robustness to interobserver delineation was assessed using the intraclass correlation coefficient (ICC). Pearson correlation coefficients (r) were calculated to determine the relationship between the features. The influence of excluding unrobust features from normal tissue complication probability (NTCP) modeling was investigated for severe oral mucositis (grade ≥3).

Results: The average DSC was 0.84 (95% confidence interval, 0.83-0.86). Most of the shape features demonstrated robustness (ICC ≥0.75), while the first-order and texture features were influenced by delineation variability. Among the three observers investigated, 42 features were sufficiently robust, out of which 36 features exhibited weak correlation (|r|<0.8). No significant difference in the robustness level was found when comparing manual segmentation by a single RO or automated segmentation with the actual clinical contour data made by treating ROs. Excluding unrobust features from the NTCP model for severe oral mucositis did not deteriorate the model performance.

Conclusion: Interobserver delineation variability had substantial impact on radiomic features of the parotid gland. Both manual and automated segmentation methods contributed similarly to this variation.

目的:评估计算机断层扫描(CT)图像中腮腺放射学特征的观察者间差异,并评估这些特征与头颈部癌症(HNC)放疗患者的相关性:材料: 采用 20 名 HNC 患者的对比增强 CT 图像。腮腺由主治放射肿瘤专家(RO)、选定的一名放射肿瘤专家和 AccuContour 自动分割软件进行分割。计算了每对观察者之间的骰子相似系数(DSC)。共提取了 107 个放射学特征,并使用类内相关系数(ICC)评估了观察者间划分的稳健性。通过计算皮尔逊相关系数(r)来确定特征之间的关系。对于严重口腔黏膜炎(等级≥3),研究了在正常组织并发症概率(NTCP)建模中排除不可靠特征的影响:结果:平均 DSC 为 0.84(95% 置信区间,0.83-0.86)。大多数形状特征都表现出稳健性(ICC ≥0.75),而一阶特征和纹理特征则受到划线可变性的影响。在接受调查的三位观察者中,42 个特征具有足够的稳健性,其中 36 个特征表现出弱相关性(|r|结论:观察者之间的划分差异对腮腺的放射学特征有很大影响。人工和自动分割方法对这种差异的影响相似。
{"title":"Interobserver delineation variability of computed tomography-based radiomic features of the parotid gland.","authors":"Kanyapat Buasawat, Sasikarn Chamchod, Todsaporn Fuangrod, Sawanee Suntiwong, Thiansin Liamsuwan","doi":"10.3857/roj.2023.00605","DOIUrl":"10.3857/roj.2023.00605","url":null,"abstract":"<p><strong>Purpose: </strong>To assess the interobserver delineation variability of radiomic features of the parotid gland from computed tomography (CT) images and evaluate the correlation of these features for head and neck cancer (HNC) radiotherapy patients.</p><p><strong>Materials and methods: </strong>Contrast-enhanced CT images of 20 HNC patients were utilized. The parotid glands were delineated by treating radiation oncologists (ROs), a selected RO and AccuContour auto-segmentation software. Dice similarity coefficients (DSCs) between each pair of observers were calculated. A total of 107 radiomic features were extracted, whose robustness to interobserver delineation was assessed using the intraclass correlation coefficient (ICC). Pearson correlation coefficients (r) were calculated to determine the relationship between the features. The influence of excluding unrobust features from normal tissue complication probability (NTCP) modeling was investigated for severe oral mucositis (grade ≥3).</p><p><strong>Results: </strong>The average DSC was 0.84 (95% confidence interval, 0.83-0.86). Most of the shape features demonstrated robustness (ICC ≥0.75), while the first-order and texture features were influenced by delineation variability. Among the three observers investigated, 42 features were sufficiently robust, out of which 36 features exhibited weak correlation (|r|<0.8). No significant difference in the robustness level was found when comparing manual segmentation by a single RO or automated segmentation with the actual clinical contour data made by treating ROs. Excluding unrobust features from the NTCP model for severe oral mucositis did not deteriorate the model performance.</p><p><strong>Conclusion: </strong>Interobserver delineation variability had substantial impact on radiomic features of the parotid gland. Both manual and automated segmentation methods contributed similarly to this variation.</p>","PeriodicalId":94184,"journal":{"name":"Radiation oncology journal","volume":"42 1","pages":"63-73"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10982058/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140320260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Radiomics in stereotactic body radiotherapy for non-small cell lung cancer: a systematic review and radiomic quality score study. 非小细胞肺癌立体定向体放射治疗中的放射组学:系统综述和放射组学质量评分研究。
Pub Date : 2024-03-01 Epub Date: 2024-02-21 DOI: 10.3857/roj.2023.00612
Ben Man Fei Cheung

Purpose: Stereotactic body radiotherapy (SBRT) has been widely utilized for curative treatment of early-stage non-small cell lung cancer (NSCLC). It has achieved good local control rate comparable to surgery. Currently, no standard risk model exists for SBRT outcome or complication prediction. Radiomics has the potential to improve clinical outcome prognostication. Here, we reviewed the current literature on the radiomic analyses of thoracic SBRT through the use of radiomic quality score (RQS).

Materials and methods: Literature search was conducted on PubMed and Embase to retrieve radiomics studies on SBRT for early NSCLC. The literature search included studies up to June 2021. Only full papers published in peer reviewed journals were included. Studies that included metastatic lung cancers or non-lung cancers were excluded. Two independent investigators evaluated each study using the RQS and resolved discrepancies through discussion.

Results: A total number of 25 studies were analysed. The mean RQS was 7.76 of a maximum score of 36. This corresponds to 21.56% of the maximum score. Lack of feature reduction strategies, external validation and open data sharing were identified as key limitations of the reviewed studies. Meanwhile, various common radiomic signatures across different studies such as gray level co-occurrence matrix Homogeneity and energy have been identified. Multiple robust radiomic models have also been reviewed that may improve outcome or complication prediction.

Conclusion: Radiomics in thoracic SBRT has a very promising future as a prognostication tool. However, larger multicenter prospective studies are required to confirm radiomic signatures. Improvement in future study methodologies can also facilitate its wider application.

目的:立体定向体放射治疗(SBRT)已被广泛用于早期非小细胞肺癌(NSCLC)的根治性治疗。它取得了与手术相当的良好局部控制率。目前,SBRT 的疗效或并发症预测还没有标准的风险模型。放射组学有望改善临床结果预后。在此,我们回顾了通过使用放射质量评分(RQS)对胸部 SBRT 进行放射学分析的现有文献:在 PubMed 和 Embase 上进行文献检索,检索有关早期 NSCLC SBRT 的放射组学研究。文献检索包括截至 2021 年 6 月的研究。仅包括发表在同行评审期刊上的论文全文。排除了包括转移性肺癌或非肺癌的研究。两名独立调查人员使用RQS对每项研究进行评估,并通过讨论解决差异:共分析了 25 项研究。平均 RQS 为 7.76,最高分为 36 分。这相当于最高分的 21.56%。缺乏特征缩减策略、外部验证和开放数据共享被认为是所审查研究的主要局限性。同时,在不同的研究中发现了各种常见的放射体征,如灰度共现矩阵同质性和能量。此外,还综述了多种稳健的放射线组学模型,这些模型可改善预后或并发症预测:结论:放射组学作为一种预后预测工具,在胸部 SBRT 中的应用前景非常广阔。然而,还需要更大规模的多中心前瞻性研究来确认放射组学特征。未来研究方法的改进也能促进其更广泛的应用。
{"title":"Radiomics in stereotactic body radiotherapy for non-small cell lung cancer: a systematic review and radiomic quality score study.","authors":"Ben Man Fei Cheung","doi":"10.3857/roj.2023.00612","DOIUrl":"10.3857/roj.2023.00612","url":null,"abstract":"<p><strong>Purpose: </strong>Stereotactic body radiotherapy (SBRT) has been widely utilized for curative treatment of early-stage non-small cell lung cancer (NSCLC). It has achieved good local control rate comparable to surgery. Currently, no standard risk model exists for SBRT outcome or complication prediction. Radiomics has the potential to improve clinical outcome prognostication. Here, we reviewed the current literature on the radiomic analyses of thoracic SBRT through the use of radiomic quality score (RQS).</p><p><strong>Materials and methods: </strong>Literature search was conducted on PubMed and Embase to retrieve radiomics studies on SBRT for early NSCLC. The literature search included studies up to June 2021. Only full papers published in peer reviewed journals were included. Studies that included metastatic lung cancers or non-lung cancers were excluded. Two independent investigators evaluated each study using the RQS and resolved discrepancies through discussion.</p><p><strong>Results: </strong>A total number of 25 studies were analysed. The mean RQS was 7.76 of a maximum score of 36. This corresponds to 21.56% of the maximum score. Lack of feature reduction strategies, external validation and open data sharing were identified as key limitations of the reviewed studies. Meanwhile, various common radiomic signatures across different studies such as gray level co-occurrence matrix Homogeneity and energy have been identified. Multiple robust radiomic models have also been reviewed that may improve outcome or complication prediction.</p><p><strong>Conclusion: </strong>Radiomics in thoracic SBRT has a very promising future as a prognostication tool. However, larger multicenter prospective studies are required to confirm radiomic signatures. Improvement in future study methodologies can also facilitate its wider application.</p>","PeriodicalId":94184,"journal":{"name":"Radiation oncology journal","volume":"42 1","pages":"4-16"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10982060/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140320261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evidence-based clinical recommendations for hypofractionated radiotherapy: exploring efficacy and safety - Part 1. Brain and head and neck. 基于证据的超分割放射治疗临床建议:疗效与安全性探讨--第一部分。脑和头颈部。
Pub Date : 2024-03-01 Epub Date: 2024-03-14 DOI: 10.3857/roj.2023.00899
Soo-Yoon Sung, Jin Ho Song, Byoung Hyuck Kim, Yoo-Kang Kwak, Kyung Su Kim, Gyu Sang Yoo, Hwa Kyung Byun, Yeon Joo Kim, Yeon-Sil Kim

Advances in radiotherapy (RT) techniques, including intensity-modulated RT and image-guided RT, have allowed hypofractionation, increasing the fraction size over the conventional dose of 1.8-2.0 Gy. Hypofractionation offers advantages such as shorter treatment times, improved compliance, and under specific conditions, particularly in tumors with a low α/β ratio, higher efficacy. It was initially explored for use in RT for prostate cancer and adjuvant RT for breast cancer, and its application has been extended to various other malignancies. Hypofractionated RT (HFRT) may also be effective in patients who are unable to undergo conventional treatment owing to poor performance status, comorbidities, or old age. The treatment of brain tumors with HFRT is relatively common because brain stereotactic radiosurgery has been performed for over two decades. However, re-irradiation of recurrent lesions and treatment of elderly or frail patients are areas under investigation. HFRT for head and neck cancer has not been widely used because of concerns regarding late toxicity. Thus, we aimed to provide a comprehensive summary of the current evidence for HFRT for brain tumors and head and neck cancer and to offer practical recommendations to clinicians faced with the challenge of choosing new treatment options.

放射治疗(RT)技术的进步,包括强度调控RT和图像引导RT,使得低分次治疗成为可能,分次治疗的剂量比传统的1.8-2.0Gy有所增加。低剂量治疗具有缩短治疗时间、提高依从性等优点,在特定条件下,尤其是对α/β比值较低的肿瘤,疗效更高。该疗法最初被探索用于前列腺癌和乳腺癌的辅助 RT 治疗,目前已扩展到其他各种恶性肿瘤。对于因表现不佳、合并症或年老而无法接受常规治疗的患者,低分次放射治疗(HFRT)也可能有效。由于脑立体定向放射外科手术已经开展了二十多年,因此使用 HFRT 治疗脑肿瘤相对比较常见。不过,对复发病灶的再次照射以及对老年或体弱患者的治疗仍在研究之中。由于担心晚期毒性,头颈部癌症的 HFRT 尚未得到广泛应用。因此,我们旨在全面总结目前脑肿瘤和头颈部癌症 HFRT 的证据,并为面临选择新治疗方案挑战的临床医生提供实用建议。
{"title":"Evidence-based clinical recommendations for hypofractionated radiotherapy: exploring efficacy and safety - Part 1. Brain and head and neck.","authors":"Soo-Yoon Sung, Jin Ho Song, Byoung Hyuck Kim, Yoo-Kang Kwak, Kyung Su Kim, Gyu Sang Yoo, Hwa Kyung Byun, Yeon Joo Kim, Yeon-Sil Kim","doi":"10.3857/roj.2023.00899","DOIUrl":"10.3857/roj.2023.00899","url":null,"abstract":"<p><p>Advances in radiotherapy (RT) techniques, including intensity-modulated RT and image-guided RT, have allowed hypofractionation, increasing the fraction size over the conventional dose of 1.8-2.0 Gy. Hypofractionation offers advantages such as shorter treatment times, improved compliance, and under specific conditions, particularly in tumors with a low α/β ratio, higher efficacy. It was initially explored for use in RT for prostate cancer and adjuvant RT for breast cancer, and its application has been extended to various other malignancies. Hypofractionated RT (HFRT) may also be effective in patients who are unable to undergo conventional treatment owing to poor performance status, comorbidities, or old age. The treatment of brain tumors with HFRT is relatively common because brain stereotactic radiosurgery has been performed for over two decades. However, re-irradiation of recurrent lesions and treatment of elderly or frail patients are areas under investigation. HFRT for head and neck cancer has not been widely used because of concerns regarding late toxicity. Thus, we aimed to provide a comprehensive summary of the current evidence for HFRT for brain tumors and head and neck cancer and to offer practical recommendations to clinicians faced with the challenge of choosing new treatment options.</p>","PeriodicalId":94184,"journal":{"name":"Radiation oncology journal","volume":"42 1","pages":"17-31"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10982054/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140320257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of adaptive radiotherapy on survival in locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiotherapy. 适应性放疗对同时接受化放疗的局部晚期鼻咽癌患者生存期的影响。
Pub Date : 2024-03-01 Epub Date: 2024-03-18 DOI: 10.3857/roj.2023.00374
Yusuke Uchinami, Koichi Yasuda, Hideki Minatogawa, Yasuhiro Dekura, Noboru Nishikawa, Rumiko Kinoshita, Kentaro Nishioka, Norio Katoh, Takashi Mori, Manami Otsuka, Naoki Miyamoto, Ryusuke Suzuki, Keiji Kobashi, Yasushi Shimizu, Jun Taguchi, Nayuta Tsushima, Satoshi Kano, Akihiro Homma, Hidefumi Aoyama

Purpose: To investigate the clinical significance of adaptive radiotherapy (ART) in locally advanced nasopharyngeal carcinoma treated with intensity-modulated radiotherapy (IMRT).

Materials and methods: Eligible patients were treated with concurrent chemoradiotherapy using IMRT. Planning computed tomography in ART was performed during radiotherapy, and replanning was performed. Since ART was started in May 2011 (ART group), patients who were treated without ART up to April 2011 (non-ART group) were used as the historical control. The Kaplan-Meier method was used to calculate overall survival (OS), locoregional recurrence-free survival (LRFS), progression-free survival (PFS), and distant metastasis-free survival (DMFS). LRFS for the primary tumor (LRFS_P) and regional lymph node (LRFS_LN) were also studied for more detailed analysis. Statistical significance was evaluated using the log-rank test for survival.

Results: The ART group tended to have higher radiation doses. The median follow-up period was 127 months (range, 10 to 211 months) in the non-ART group and 61.5 months (range, 5 to 129 months) in the ART group. Compared to the non-ART group, the ART group showed significantly higher 5-year PFS (53.8% vs. 81.3%, p = 0.015) and LRFS (61.2% vs. 85.3%, p = 0.024), but not OS (80.7% vs. 80.8%, p = 0.941) and DMFS (84.6% vs. 92.7%, p = 0.255). Five-year LRFS_P was higher in the ART group (61.3% vs. 90.6%, p = 0.005), but LRFS_LN did not show a significant difference (91.9% vs. 96.2%, p = 0.541).

Conclusion: Although there were differences in the patient backgrounds between the two groups, this study suggests the potential effectiveness of ART in improving locoregional control, especially in the primary tumor.

目的:研究适应性放疗(ART)在局部晚期鼻咽癌调强放疗(IMRT)中的临床意义:符合条件的患者同时接受了IMRT化放疗。在放疗期间进行 ART 计划计算机断层扫描,并进行重新扫描。由于 ART 于 2011 年 5 月开始(ART 组),因此将 2011 年 4 月之前未接受 ART 治疗的患者(非 ART 组)作为历史对照。采用卡普兰-梅耶法计算总生存期(OS)、无局部复发生存期(LRFS)、无进展生存期(PFS)和无远处转移生存期(DMFS)。为了进行更详细的分析,还研究了原发肿瘤(LRFS_P)和区域淋巴结(LRFS_LN)的无局部复发生存率。统计意义采用生存率对数秩检验进行评估:结果:ART 组的放射剂量较高。非 ART 组的中位随访时间为 127 个月(10 至 211 个月),ART 组为 61.5 个月(5 至 129 个月)。与非ART组相比,ART组的5年PFS(53.8% vs. 81.3%,P = 0.015)和LRFS(61.2% vs. 85.3%,P = 0.024)明显更高,但OS(80.7% vs. 80.8%,P = 0.941)和DMFS(84.6% vs. 92.7%,P = 0.255)则不高。ART组的5年LRFS_P更高(61.3% vs. 90.6%,p = 0.005),但LRFS_LN没有显著差异(91.9% vs. 96.2%,p = 0.541):尽管两组患者的背景存在差异,但本研究表明 ART 在改善局部控制,尤其是原发肿瘤的局部控制方面具有潜在的有效性。
{"title":"Impact of adaptive radiotherapy on survival in locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiotherapy.","authors":"Yusuke Uchinami, Koichi Yasuda, Hideki Minatogawa, Yasuhiro Dekura, Noboru Nishikawa, Rumiko Kinoshita, Kentaro Nishioka, Norio Katoh, Takashi Mori, Manami Otsuka, Naoki Miyamoto, Ryusuke Suzuki, Keiji Kobashi, Yasushi Shimizu, Jun Taguchi, Nayuta Tsushima, Satoshi Kano, Akihiro Homma, Hidefumi Aoyama","doi":"10.3857/roj.2023.00374","DOIUrl":"10.3857/roj.2023.00374","url":null,"abstract":"<p><strong>Purpose: </strong>To investigate the clinical significance of adaptive radiotherapy (ART) in locally advanced nasopharyngeal carcinoma treated with intensity-modulated radiotherapy (IMRT).</p><p><strong>Materials and methods: </strong>Eligible patients were treated with concurrent chemoradiotherapy using IMRT. Planning computed tomography in ART was performed during radiotherapy, and replanning was performed. Since ART was started in May 2011 (ART group), patients who were treated without ART up to April 2011 (non-ART group) were used as the historical control. The Kaplan-Meier method was used to calculate overall survival (OS), locoregional recurrence-free survival (LRFS), progression-free survival (PFS), and distant metastasis-free survival (DMFS). LRFS for the primary tumor (LRFS_P) and regional lymph node (LRFS_LN) were also studied for more detailed analysis. Statistical significance was evaluated using the log-rank test for survival.</p><p><strong>Results: </strong>The ART group tended to have higher radiation doses. The median follow-up period was 127 months (range, 10 to 211 months) in the non-ART group and 61.5 months (range, 5 to 129 months) in the ART group. Compared to the non-ART group, the ART group showed significantly higher 5-year PFS (53.8% vs. 81.3%, p = 0.015) and LRFS (61.2% vs. 85.3%, p = 0.024), but not OS (80.7% vs. 80.8%, p = 0.941) and DMFS (84.6% vs. 92.7%, p = 0.255). Five-year LRFS_P was higher in the ART group (61.3% vs. 90.6%, p = 0.005), but LRFS_LN did not show a significant difference (91.9% vs. 96.2%, p = 0.541).</p><p><strong>Conclusion: </strong>Although there were differences in the patient backgrounds between the two groups, this study suggests the potential effectiveness of ART in improving locoregional control, especially in the primary tumor.</p>","PeriodicalId":94184,"journal":{"name":"Radiation oncology journal","volume":"42 1","pages":"74-82"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10982056/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140320259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pulsed low-dose rate radiotherapy for recurrent bone sarcomas: case reports and brief review 针对复发性骨肉瘤的脉冲低剂量放射治疗:病例报告和简要回顾
Pub Date : 2024-02-13 DOI: 10.3857/roj.2023.00815
Ru Xin Wong, Zubin Master, Eric Pang, Valerie Yang, W. S. Looi
{"title":"Pulsed low-dose rate radiotherapy for recurrent bone sarcomas: case reports and brief review","authors":"Ru Xin Wong, Zubin Master, Eric Pang, Valerie Yang, W. S. Looi","doi":"10.3857/roj.2023.00815","DOIUrl":"https://doi.org/10.3857/roj.2023.00815","url":null,"abstract":"","PeriodicalId":94184,"journal":{"name":"Radiation oncology journal","volume":"120 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139780865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Radiation oncology journal
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1